Thyrocare Technologies Ltd

- There is no mention of any current or planned fundraising through debt or equity in the provided transcript. - The company maintains a strong balance sheet with net cash and investments of INR230 crores and zero debt as of March 31, 2026. - The capital expenditure is being managed within cash flows, with maintenance capex around INR40 crores and calibrated investments in growth areas like genomics and specialty testing. - Focus remains on asset-light franchise expansion rather than heavy capex or external fundraising. - The management emphasizes investing operating leverage back into growth while preserving margins rather than seeking external funding.

- FY'26 capex payout was around INR20-35 crores, relatively low compared to operating cash flow. - Total capitalization during FY'26 was around INR35 crores, including new labs and genomics investments. - Maintenance capex is roughly around INR40 crores, with expansion capex expected in a similar range. - New lab openings: 7 labs added in FY'26 (Bhagalpur, Mandi, Roorkee, Kashmir, Davanagere, Vijaywada, Gwalior). - Focus on franchise addition as a primary growth driver, which is asset-light and limits heavy capex needs. - Investments in genomic and specialty diagnostics with capex estimates around INR5-8 crores. - Major investments for specialty diagnostics are on operational expenditure (field force of ~40 people). - Future capex expected to continue as needed, aligned with growth, but calibrated to protect margins. - Emphasis on technology, new labs, and supply chain improvements to sustain margins and growth.

- Specialty testing market opportunity estimated at INR 7,000 to 10,000 crores over 2-3 years, indicating growth potential in specialty and allied services. - Q4 FY26 test volume growth surged to ~29%, driven by competitive pricing in biochemistry tests. - Expected mid- to high-teens revenue growth for FY27, primarily volume-driven (~75%), with mix contributing ~25%. - Franchise addition targeted at ~500 per quarter, maintaining steady expansion and increasing average revenue per franchisee due to expanded test menu. - No price hikes planned; growth driven by volume and service mix improvements. - Specialty segment is nascent; margin impact expected after FY28, with EBITDA margins stable around 32-34% in near term. - Insurance business grew ~45% YoY, continuing as a focus area with potential growth aligned to overall insurance industry expansion (~25% growth).

- FY '26 reported a strong profit after tax (PAT) of INR163 crores, up 81% YoY, with EPS of INR2.99, up 64% YoY. - Expect mid- to high-teens growth in test volumes and revenue in FY '27, driven mainly by volume (~75%) and mix (~25%). - Specialty testing is nascent in FY '27; EBITDA margins to remain stable around 32%-34%, with no significant margin expansion expected from specialty until FY '28 onwards. - Operating leverage benefits will be largely reinvested into growth; margin preservation remains a priority. - Franchise expansion and partnership growth, plus new specialty and allied services, underpin future growth. - Insurance business grew ~45% YoY; expected to remain a focused growth area. - Overall, sustained volume growth and mix improvement should drive steady earnings growth over next 2-3 years.

The transcript does not explicitly mention any details about the current or expected order book or pending orders for Thyrocare Technologies Limited. The discussion focuses on: - Market opportunity in specialty testing (INR7,000-10,000 crores estimate). - Growth in insurance business and allied segments. - Franchise expansion running at about 500 franchises per quarter. - Test volume growth and expansion in test menu. - Capacity utilization and lab expansion. - Financial performance and margin outlook. No direct information on orderbook or pending orders is provided in the available pages.